VBI Vaccines (VBIVQ) 10-Q 15 May 17 2017 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2017	May 11, 2017
Document And Entity Information
Entity Registrant Name	VBI Vaccines Inc/BC
Entity Central Index Key	764,195
Document Type	10-Q
Document Period End Date	Mar. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		40,060,622
Trading Symbol	VBIV
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2,017

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
CURRENT ASSETS
Cash	$ 23,509	$ 32,282
Accounts receivable, net	43	10
Inventory, net	959	830
Other current assets	1,272	1,236
Total current assets	25,783	34,358
NON-CURRENT ASSETS
Long-term deposits	171	167
Other long term assets	555	487
Property and equipment, net	2,053	1,850
Intangible assets, net	59,977	59,507
Goodwill	8,450	8,385
Total non-current assets	71,206	70,396
TOTAL ASSETS	96,989	104,754
CURRENT LIABILITIES
Accounts payable	1,480	2,018
Other current liabilities	6,304	5,562
Deferred revenues		34
Total current liabilities	7,784	7,614
NON-CURRENT LIABILITIES
Long-term debt, net of debt discount of $3,056 and $3,344, respectively	12,244	11,956
Long-term deferred tax liability		428
Liabilities for severance pay	433	356
Deferred revenues, net of current portion	669	669
Total non-current liabilities	13,346	13,409
COMMITMENTS AND CONTINGENCIES (NOTE 10)
STOCKHOLDERS' EQUITY
Common shares (unlimited authorized; no par value) (40,060,622 and 40,018,495 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively)	133,410	133,312
Additional paid-in capital	59,137	58,595
Accumulated other comprehensive income loss	(3,070)	(3,196)
Accumulated deficit	(113,618)	(104,980)
Total stockholders' equity	75,859	83,731
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 96,989	$ 104,754

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Long-term debt, net of debt discount	$ 3,056	$ 3,344
Common stock, authorized unlimited	Unlimited	Unlimited
Common stock, no par value
Common stock, shares issued	40,060,622	40,018,495
Common stock, shares outstanding	40,060,622	40,018,495

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Statement [Abstract]
Revenues	$ 127	$ 48
Operating expenses:
Cost of revenue	1,275	377
Research and development	4,654	254
General and administration	3,045	1,980
Total operating expenses	8,974	2,611
Loss from operations	(8,847)	(2,563)
Interest expense, net	(704)	(25)
Foreign exchange gain	482	1,509
Loss before incomes taxes	(9,069)	(1,079)
Income tax benefit	431
NET LOSS	$ (8,638)	$ (1,079)
Net loss per share of common shares, basic and diluted	$ (0.22)	$ (0.06)
Weighted-average number of common shares outstanding, basic and diluted	40,026,270	18,914,986
Other comprehensive income (loss): Foreign currency translation adjustments	$ 126	$ (691)
COMPREHENSIVE LOSS	$ (8,512)	$ (1,770)

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - 3 months ended Mar. 31, 2017 - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Loss - Foreign Currency Translation Adjustments [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2016	$ 133,312	$ 58,595	$ (3,196)	$ (104,980)	$ 83,731
Balance, Shares at Dec. 31, 2016	40,018,495
Stock-based compensation	$ 39	542			581
Stock-based compensation, Shares	23,250
Common shares issued for services	$ 43				$ 43
Common shares issued for services, Shares	12,500				69,000
Common shares issued on exercise of stock options	$ 16				$ 16
Common shares issued on exercise of stock options, Shares	6,377				(19,000)
Net loss				(8,638)	$ (8,638)
Foreign currently transaction adjustments			126		126
Balance at Mar. 31, 2017	$ 133,410	$ 59,137	$ (3,070)	$ (113,618)	$ 75,859
Balance, Shares at Mar. 31, 2017	40,060,622

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (8,638)	$ (1,079)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization	171	132
Deferred taxes	(431)
Stock-based compensation	624
Amortization of debt discount	288
Net change in operating working capital items, net of business acquisitions:
(Increase) decrease in accounts receivable	(32)	174
(Increase) decrease in inventory	(78)	(4)
(Increase) decrease in other current assets	(28)	68
(Decrease) increase in other long-term assets	(27)	3
(Decrease) increase in accounts payable	(609)	28
(Decrease) increase in deferred revenues, including related parties	(73)	(806)
(Decrease) increase in other current liabilities	589	88
Net cash flows used in operating activities	(8,244)	(1,396)
INVESTING ACTIVITIES
Changes in long-term deposits		(27)
Purchase of property and equipment	(266)	(106)
Net cash flows provided by investing activities	(266)	(133)
FINANCING ACTIVITIES
Proceeds from issuance of common shares for cash, upon exercise of stock options	16
Net cash flows provided by financing activities	16
Effect of exchange rates on cash	(279)	13
CHANGE IN CASH FOR THE PERIOD	(8,773)	(1,516)
CASH, BEGINNING OF PERIOD	32,282	12,476
CASH, END OF PERIOD	23,509	10,960
Supplementary information:
Interest paid	450	25
Capital expenditures included in other current liabilities	$ 76

Nature of Business and Continua

Nature of Business and Continuation of Business	3 Months Ended
	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business and Continuation of Business	1. NATURE OF BUSINESS AND CONTINUATION OF BUSINESS Corporate Overview VBI Vaccines Inc. (formerly SciVac Therapeutics, Inc.) and its subsidiaries (collectively referred to as the “Company,” “we,” “us,” “our” or “VBI”) was incorporated under the laws of British Columbia, Canada on April 9, 1965. The Company has the following wholly-owned subsidiaries, VBI Vaccines (Delaware) Inc., a Delaware corporation (“VBI DE”); VBI DE’s wholly-owned subsidiary, Variation Biotechnologies (US), Inc., a Delaware corporation (“VBI US”); Variation Biotechnologies, Inc. a Canadian company (“VBI Cda”) and the wholly-owned subsidiary of VBI US; SciVac Ltd. an Israeli company (“SciVac”); and SciVac USA, LLC. a Florida limited liability company (“SciVac US”) and the wholly owned subsidiary of SciVac. The Company’s registered office is located at 1200 Waterfront Centre, 200 Burrard Street, Vancouver, Canada V6C 3L6 with its principal office located at 222 Third Street, Suite 2241, Cambridge, Massachusetts 02142. In addition, the Company has manufacturing facilities located in Rehovot, Israel and research facilities located in Ottawa, Ontario, Canada. The Company operates in one segment and therefore segment information is not presented. Principal Operations We are a commercial stage biopharmaceutical company developing next generation vaccines to address unmet needs in infectious disease and immuno-oncology. VBI’s first marketed product is Sci-B-Vac™, a hepatitis B (“HBV”) vaccine that mimics all three viral surface antigens of the hepatitis B virus. Sci-B-Vac™ is approved for use in Israel and 14 other countries. Recently, VBI completed a post-marketing Phase IV clinical study in Israel to confirm a new in-house reference standard for regulatory and quality control purposes. Sci-B-Vac™ has not yet been approved by the U.S. Food and Drug Administration (the “FDA”), the European Medicines Agency (the “EMA”) or Health Canada (“HC”). VBI is currently developing a Phase III clinical program to obtain FDA, EMA, and HC market approvals for commercial sale of Sci-B-Vac™ in the United States, Europe, and Canada, respectively. Our wholly-owned subsidiary, SciVac Ltd., manufactures Sci-B-Vac™ in Rehovot, Israel. Following our merger with VBI DE on May 6, 2016 (the “VBI-SciVac Merger”), we are also advancing our two platform technologies – our Enveloped Virus-Like Particle (“eVLP”) platform technology and our Lipid Particle Vaccine (“LPV”) technology. Our eVLP platform technology enables the development of enveloped virus-like particle vaccines that closely mimic the target virus to elicit a potent immune response. We are advancing a pipeline of eVLP vaccines, with lead programs in both infectious disease, with our congenital cytomegalovirus (“CMV”) vaccine, and in immuno-oncology, with our therapeutic glioblastoma multiforme (“GBM” or “glioblastoma”) vaccine candidate. Our LPV thermostability technology is a proprietary formulation of lipids and process that allows vaccines and biologics to preserve stability, potency, and safety at temperatures outside of the most common cold chain storage requirements of 2 o o Liquidity and Going Concern The Company has a limited operating history and faces a number of risks, including but not limited to, uncertainties regarding demand and market acceptance of the Company’s products and reliance on major customers. The Company anticipates that it will continue to incur significant operating costs and losses in connection with the development of its products. The Company has an accumulated deficit of $113,618 as of March 31, 2017 and cash outflows from operating activities of $8,244 for the three months ended March 31, 2017. The Company will require significant additional funds to conduct clinical and non-clinical studies, achieve regulatory approvals, and, subject to such approvals, commercially launch its products. The Company plans to finance future operations with a combination of existing cash reserves, proceeds from the issuance of equity securities, the issuance of additional debt, and revenues from potential collaborations, if any. There is no assurance the Company will manage to obtain these sources of financing. The above conditions raise substantial doubt about the Company’s ability to continue as a going concern. The report of our independent registered public accounting firm on our consolidated financial statements for the year ended December 31, 2016 contains an explanatory paragraph regarding our ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern.

Significant Accounting Policies

Significant Accounting Policies	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Significant Accounting Policies	2. SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Consolidation The Company’s fiscal year ends on December 31 of each calendar year. The accompanying unaudited condensed consolidated financial statements have been prepared in U.S. dollars (“USD”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”), the instructions to Form 10-Q and the provisions of Regulation S-X pertaining to financial statements. Accordingly, certain information and footnote disclosures normally included in the financial statements prepared in accordance United States of America generally accepted accounting principles (“U.S. GAAP”), have been condensed or omitted pursuant to such rules and regulations. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and are not necessarily indicative of the results to be expected for any future period or the entire fiscal year. The December 31, 2016 consolidated balance sheet in this document was derived from the audited consolidated financial statements and does not include all of the disclosures required by U.S. GAAP. The condensed consolidated financial statements and notes included in this quarterly report on Form 10-Q (this “Form 10-Q”) should be read in conjunction with the financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 (the “2016 10-K”), as filed with the SEC on March 20, 2017. The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries: SciVac, SciVac USA, and from May 6, 2016 the accounts of VBI DE, VBI US and VBI Cda. Intercompany balances and transactions between the Company and its subsidiaries are eliminated in the condensed consolidated financial statements. In the opinion of management, these condensed consolidated financial statements include all adjustments and accruals of a normal and recurring nature necessary to fairly state the results of the periods presented. The results for periods are not necessarily indicative of results to be expected for the full year or for any future periods. Significant Accounting Policies The significant accounting policies used in the preparation of these condensed consolidated financial statements are disclosed in the 2016 10-K, and there have been no changes to the Company’s significant accounting policies during the three months ended March 31, 2017. Foreign currency The functional and reporting currency of the Company is the USD. Each of the Company’s subsidiaries determines its own respective functional currency, and this currency is used to separately measure each entity’s financial position and operating results. Assets and liabilities of foreign operations with a different functional currency from that of the Company are translated at the closing rate at the end of each reporting period. Profit or loss items are translated at average exchange rates for all the relevant periods. All resulting translation differences are recognized as a component of accumulated other comprehensive loss. Foreign exchange gains and losses arising from transactions denominated in a currency other than the functional currency of the entity involved, are included in operating results. Use of Estimates Preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual amounts could differ from the estimates made. We continually evaluate estimates used in the preparation of the condensed consolidated financial statements for reasonableness. Appropriate adjustments, if any, to the estimates used are made prospectively based upon such periodic evaluation. The significant areas of estimation include determining the deferred tax valuation allowance, the estimated lives of property and equipment and intangible assets, the inputs in determining the fair value of equity based awards and warrants issued as well as the values ascribed to assets acquired and liabilities assumed in the business combination. Actual results may differ from those estimates. Goodwill and In-Process Research and Development The Company’s intangibles determined to have indefinite useful lives including in-process research and development (“IPR&D”) and goodwill, are tested for impairment annually, or more frequently if events or circumstances indicate that the assets might be impaired. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination. Such circumstances could include, but are not limited to: (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. When evaluating goodwill for impairment, we may first perform an assessment qualitatively whether it is more likely than not that a reporting unit’s carrying amount exceeds its fair value, referred to as a “step zero” approach. If, based on the review of the qualitative factors, we determine it is not more likely than not that the fair value of a reporting unit is less than its carrying value, we would bypass the two-step impairment test. If we conclude that it is more likely than not that a reporting unit’s fair value is less than its carrying amount, we would perform the first step (“step one”) of the two-step impairment test. Step 1 compares the fair value of the Company’s reporting unit to which goodwill was allocated to its carrying value. If the fair value of the reporting unit exceeds its carrying value, no further analysis is necessary. If the carrying amount of the reporting unit exceeds its fair value, Step 2 must be completed to quantify the amount of impairment. Step 2 calculates the implied fair value of goodwill by deducting the fair value of all tangible and intangible assets, excluding goodwill, of the reporting unit, from the fair value of the reporting unit as determined in Step 1. The implied fair value of goodwill determined in this step is compared to the carrying value of goodwill. If the implied fair value of goodwill is less than the carrying value of goodwill, an impairment loss, equal to the difference, is recognized. The Company has established August 31 st The costs of rights to IPR&D projects acquired in an asset acquisition are expensed in the consolidated statements of operations unless the project has an alternative future use. These costs include initial payments incurred prior to regulatory approval in connection with research and development agreements that provide rights to develop, manufacture, market and/or sell pharmaceutical products. IPR&D acquired in a business combination is capitalized as an intangible asset and tested for impairment at least annually until commercialization, after which time the IPR&D is amortized over its estimated useful life. The impairment test compares the carrying amount of the IPR&D asset to its fair value. If the carrying amount exceeds the fair value of the asset, such excess is recorded as an impairment loss. Fair value measurements of financial instruments Accounting guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The accounting guidance outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company uses quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows: Level 1 — Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 — Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities. Level 3 — Valuations based on inputs that are unobservable and models that are significant to the overall fair value measurement. Financial instruments recognized in the condensed consolidated balance sheet consist of cash, accounts receivable and other current assets, accounts payable and other current liabilities. The Company believes that the carrying value of its current financial instruments approximates their fair values due to the short-term nature of these instruments. The Company does not hold any derivative financial instruments. The carrying amounts of the Company’s long-term assets and long-term liabilities approximate their respective fair values. At March 31, 2017 and December 31, 2016, the fair value of our outstanding debt is estimated to be approximately $15,419 and $15,012, respectively. In determining the fair value of the long-term debt as of March 31, 2017 and December 31, 2016 the Company used the following assumptions: March 31, 2017 December 31, 2016 Long-term debt: Interest rate 12.0 % 12.0 % Discount rate 11.5 % 13.5 % Expected time to payment in months 32 35

New Accounting Pronouncements

New Accounting Pronouncements	3 Months Ended
	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
New Accounting Pronouncements	3. NEW ACCOUNTING PRONOUNCEMENTS Recently Adopted Accounting Pronouncements Stock Compensation In March 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (the “ASU”) No. 2016-09, “Compensation - Stock Compensation (Topic 718),” which simplifies several aspects of the accounting for share-based payment award transactions, including the income tax consequences, classification of awards as either equity or liabilities, classification on the statement of cash flows and accounting for forfeitures. ASU No. 2016-09 is effective for fiscal years beginning after December 15, 2016, including periods within those fiscal years. Our adoption of this ASU in the first quarter of 2017 did not have a material impact on our condensed consolidated financial statements. Cash Flow Classification The FASB issued ASU 2016-15, an accounting standard that affects the classification of certain cash receipts and cash payments on the statement of cash flows. The standard provides guidance on eight issues: debt prepayment or extinguishment costs, settlement of zero-coupon bonds or bonds issued at a discount with insignificant cash coupon, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees, beneficial interests in securitization transactions, separately identifiable cash flows and applying the predominance principle. The standard is effective for public business entities for fiscal years beginning after December 15, 2017 including periods within those fiscal years. The FASB issued ASU 2016-18, an accounting standard that requires companies to include cash and cash equivalents that have restrictions on withdrawal or use in total cash and cash equivalents on the statement of cash flows. The standard does not define restricted cash or restricted cash equivalents, but companies will need to disclose the nature of the restrictions. The standard is effective for public business entities for fiscal years beginning after December 15, 2017 including interim periods within those fiscal years. Our adoption of these ASUs in the first quarter of 2017 did not have a material impact on our condensed consolidated financial statements. Recently Issued Accounting Standards, not yet Adopted Revenue from Contracts with Customers In May 2014, the FASB issued Accounting Standards Update No. 2014-09 , Leases In February 2016 the FASB issued ASU 2016-02: Leases. The ASU introduces a lessee model that results in most leases impacting the balance sheet by requiring reporting entities to recognize lease assets and lease liabilities for substantially all lease arrangements. The new standard also aligns many of the underlying principles of the new lessor model with those in ASC 606, the FASB’s new revenue recognition standard (e.g., those related to evaluating when profit can be recognized). Furthermore, the ASU addresses other concerns related to the current leases model. For example, the ASU eliminates the requirement in current U.S. GAAP for an entity to use bright-line tests in determining lease classification. The update is Effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact this new guidance will have on our financial statements and related disclosures. Accounting for Income Taxes on Intercompany Transfers The FASB recently issued ASU 2016-16, an accounting standard that requires the seller and buyer to recognize at the transaction date the current and deferred income tax consequences of intercompany asset transfers. The FASB expects the new standard to cause volatility in companies’ effective tax rates, particularly for those that transfer intangible assets to subsidiaries. The standard is effective for public business entities for fiscal years beginning after December 15, 2017 including interim periods within those fiscal years. While the Company continues to assess the potential impact of this standard, the adoption of this standard is not expected to have a material impact on our financial statements. Recognition and Measurement of Financial Assets and Financial Liabilities In January 2016, the FASB issued ASU 2016-01, “Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities”. This update will change the income statement impact of equity investments held by an entity; disclosures related to fair value of financial instruments and presentation of financial assets and liabilities. ASU 2016-01 is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Entities must apply the standard using a cumulative-effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption. Except for certain early application guidance, early adoption is not permitted. The Company is currently assessing the impact that adopting this new ASU will have on our financial statements and footnote disclosures. Simplifying the Test for Goodwill Impairment In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” which has eliminated Step 2 from the goodwill impairment test. Under Step 2, an entity had to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities following the procedure that would be required in determining the fair value of assets acquired and liabilities assumed in a business combination. Under the amendments in this update, an entity should perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. ASU 2017-04 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. While the Company continues to assess the potential impact of this standard, the adoption of this standard is not expected to have a material impact on its financial statements.

Intangibles

Intangibles	3 Months Ended
	Mar. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Intangibles	4. INTANGIBLES March 31, 2017 Gross Carrying amount Accumulated Amortization Currency Translation Net Book Value Patents $ 669 $ (349 ) $ 17 $ 337 IPR&D assets 61,500 - (1,860 ) 59,640 $ 62,169 $ (349 ) $ (1,843 ) $ 59,977 December 31, 2016 Gross Carrying amount Accumulated Amortization Currency Translation Net Book Value Patents $ 669 $ (334 ) $ (4 ) $ 331 IPR&D assets 61,500 - (2,324 ) 59,176 $ 62,169 $ (334 ) $ (2,328 ) $ 59,507 The Company amortizes intangible assets with finite lives on a straight-line basis over their estimated useful lives. Amortization related to the IPR&D assets relate to the May 6, 2016 VBI-SciVac Merger and will not begin amortizing until the Company commercializes its products. Future costs incurred to extend the life of the patents will be expensed.

Loss Per Share of Common Shares

Loss Per Share of Common Shares	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Loss Per Share of Common Shares	5. LOSS PER SHARE OF COMMON SHARES Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common shares outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as warrants, and stock options, which would result in the issuance of incremental shares of common shares unless such effect is anti-dilutive. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as their effect would be anti-dilutive. These potentially dilutive securities are more fully described in Note 8, Stockholders’ Equity and Additional Paid-in Capital. The following potentially dilutive securities outstanding at March 31, 2017 and 2016 have been excluded from the computation of diluted weighted average shares outstanding, as they would be antidilutive: March 31, 2017 March 31, 2016 Warrants 2,068,824 - Stock options and equity awards 3,120,525 - 5,189,349 -

Long-term Debt

Long-term Debt	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Long-term Debt	6. LONG-TERM DEBT As at March 31, 2017 and the December 31, 2016, the unamortized debt discount is as follows: March 31, 2017 December 31, 2016 Long-term debt, net of deferred financing costs and unamortized debt discount based on an imputed interest rate of 20.5% of $3,056 and $3,344 at March 31, 2017 and December 31, 2016, respectively $ 12,244 $ 11,956 As a result of the VBI-SciVac Merger, the Company through VBI DE assumed a term loan facility with Perceptive Credit Holdings, LP (the “Lender”) in the amount of $6,000 (the “Facility”), with an initial advance of $3,000 drawn down on prior to the Merger. As of the merger date, the Company assumed an amount of $2,361 in the Facility. On December 6, 2016, the Company amended the Facility (the “Amended Facility”) and raised an additional $13,200 which was combined with the remaining balance from the Facility of $1,800. The total principal outstanding at March 31, 2017, including the $300 exit fee discussed below, is $15,300 before the net deferred financing costs and unamortized debt discount of $3,056. Borrowings under the Amended Facility are secured by all of VBI assets. The principal on the Amended Facility accrues interest at an annual rate equal to the greater of (a) one-month LIBOR (subject to a 5.00% cap) or (b) 1.00%, plus the Applicable Margin. The Applicable Margin will be 11.00%. The first eighteen months are interest only. The interest rate as of March 31, 2017 was 12%. Upon the occurrence of an event of default, and during the continuance, of an event of default, the Applicable Margin, defined above, will be increased by 4.00% per annum. This term loan facility matures December 6, 2019 and includes both financial and non-financial covenants, including a minimum cash balance requirement. The Company was in compliance with these covenants as of March 31, 2017. Pursuant to the Amended Facility, the Company agreed to appoint a representative of Perceptive Credit on our Board who is also a portfolio manager of the Company’s largest shareholder. The Company’s obligations under the Amended Facility are secured on a senior basis by a lien on substantially all of the assets of the Company and its U.S. and Canadian subsidiaries and guaranteed by the Company and its U.S. and Canadian subsidiaries. The Amended and Restated Credit Agreement also contains customary events of default. In connection with the Amended Facility, on December 6, 2016 the Company issued to the lender two tranches of warrants. The first tranche was a warrant to purchase 363,771 common shares at an exercise price of $4.13 per share and the second tranche was a warrant to purchase 1,341,282 common shares at an exercise price per share of $3.355. The total proceeds attributed to the warrants was $2,793 based on the relative fair value of the warrants as compared to the sum of the fair values of the warrants and debt. This resulted in the debt being issued at a discount. The Company incurred $360 of debt issuance costs and is required to pay an exit fee of $300 upon full repayment of the debt resulting in additional debt discount. The total debt discount of $3,453 is being charged to interest expense using the effective interest method over the term of the debt. As of March 31, 2017, the unamortized debt discount is $3,056. The Company recorded $288 of interest expense related to the amortization of the debt discount during the three months ended March 31, 2017. The following table summarizes the future principal payments that the Company expects to make for long-term debt: Period ending March 31, Principal payments on Amended Facility and exit fee 2017 $ - 2018 1,600 2019 13,700 $ 15,300

Deferred Revenue and Related Pa

Deferred Revenue and Related Party Transactions	3 Months Ended
	Mar. 31, 2017
Deferred Revenue Disclosure [Abstract]
Deferred Revenue and Related Party Transactions	7. DEFERRED REVENUE AND RELATED PARTY TRANSACTIONS i. Prior to the VBI-SciVac Merger, one of the Company’s directors was also the chairman of the board of Kevelt AS (“Kevelt”), a wholly owned subsidiary of OAO Pharmsynthez (“Pharmsynthez”), a shareholder of the Company and was also the chairman of the board of Pharmsynthez. Following the VBI-SciVac Merger, in accordance with the merger agreement, this director resigned. On April 26, 2013, SciVac entered into a Development and Manufacturing Agreement (“DMA”) with Kevelt, pursuant to which SciVac agreed to develop the manufacturing process for the production of clinical and commercial quantities of certain materials in drug substance form. On July 30, 2016, the Company received a letter of termination from Kevelt, in part containing a request for refund of $2.5 million it had previously transferred to the Company. On March 28, 2017, the Company’s legal counsel provided the requested documentation, indicating that the amount owed to Kevelt is not $800 but rather $690 less any acquisition costs (as defined in the DMA). The Company’s legal counsel proposed a settlement together with mutual waivers of any claims whereby the Company would remit the original $800 as follows: 50% (i.e. $400) to be paid in cash and 50% (i.e. $400) through the issuance of the Company’s common shares. ii. SciVac entered into a services agreement with OPKO Biologics Ltd. (“OPKO Bio”), a wholly-owned subsidiary of OPKO Health, Inc., a related party shareholder of the Company, dated as of March 15, 2015 as amended on January 25, 2016, pursuant to which SciVac agreed to provide certain aseptic process filling services to OPKO Bio. The terms of the services agreement are based on market rates and comparable to other non-related party service agreements. See Note 6, for Facility from a lender that is also affiliated with the Company’s largest shareholder. Three months ended March 31 2017 2016 Services revenues from related parties: OPKO Bio $ 1 $ 7 Subsequent to the VBI-SciVac Merger on May 6, 2016, Kevelt and Pharmsynthez are no longer considered related parties due to the common shareholder no longer having significant influence.

Stockholders' Equity and Additi

Stockholders' Equity and Additional Paid-in Capital	3 Months Ended
	Mar. 31, 2017
Equity [Abstract]
Stockholders' Equity and Additional Paid-in Capital	8. STOCKHOLDERS’ EQUITY AND ADDITIONAL PAID-IN CAPITAL Stock option plans The Company’s stock option plans are approved by and administered by the Company’s board of directors (the “Board”) and its Compensation Committee. The Board designates, in connection with recommendations from the Compensation Committee, eligible participants to be included under the plan, and designates the number of options, exercise price and vesting period of the new options. 2006 VBI US Stock Option Plan No further options will be issued under the 2006 VBI US Stock Option Plan (the “2006 Plan”). As at March 31, 2017, there were 1,314 options outstanding under the 2006 Plan. 2013 Stock Incentive Plan No further options will be issued under the 2013 Equity Incentive Plan (the “2013 Plan”). As at March 31, 2017, there were 5 options outstanding under the 2013 Plan. 2014 Equity Incentive Plan No further options will be issued under the 2014 Equity Incentive Plan (the “2014 Plan”). As at March 31, 2017, there were 735 options outstanding under the 2014 Plan. 2016 VBI Equity Incentive Plan The 2016 VBI Equity Incentive Plan (the “2016 Plan”) is a rolling incentive plan that sets the number of common shares issuable under the 2016 Plan, together with any other security-based compensation arrangement of the Company, at a maximum of 10% of the aggregate common shares issued and outstanding on a non-diluted basis at the time of any grant under the 2016 Plan. The 10% maximum is inclusive of options granted under all equity incentive plans. The 2016 Plan is an omnibus equity incentive plan pursuant to which the Company may grant equity and equity-linked awards to eligible participants in order to promote the success of the Company following the VBI-SciVac Merger by providing a means to offer incentives and to attract, motivate, retain and reward persons eligible to participate in the 2016 Plan. Grants under the 2016 Plan include a grant or right consisting of one or more options, stock appreciation rights (“SARs”), restricted share units (“RSUs”), performance share units (“PSUs”), shares of restricted stock or other such award as may be permitted under the 2016 Plan. As at March 31, 2017, there were 411 options and 656 stock awards outstanding under the 2016 Plan. The aggregate number of common shares remaining available for issuance for awards under this plan total 585 at March 31, 2017. Activity related to stock options is as follows (in thousands, except for weighted average exercise price): Number of Stock Options Weighted Average Exercise Price Balance outstanding at December 31, 2016 2,168 $ 4.45 Granted 316 $ 3.63 Exercised (19 ) $ 3.10 Balance outstanding at March 31, 2017 2,465 $ 4.36 Exercisable at March 31, 2017 1,396 $ 4.42 Options expected to vest at March 31, 2017 1,069 $ 4.29 Information relating to restricted stock units is as follow (in thousands, except for weighted average fair value at grant date): Number of Stock Awards Weighted Average Fair Value at Grant Date Unvested shares outstanding at December 31, 2016 639 $ 3.88 Granted 57 $ 4.72 Vested and exercised (7 ) $ 5.49 Forfeited (33 ) $ 3.90 Unvested shares outstanding at March 31, 2017 656 $ 3.93 The fair value of the options expected to vest is recognized as an expense on a straight-line basis over the vesting period. The total stock-based compensation expense recorded in the three months ended March 31, 2017 and 2016 was as follows: Three months ended March 31 2017 2016 Research and development $ 185 $ - General and administrative 423 - Cost of revenues 16 - Total stock-based compensation expense $ 624 $ -

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	9. INCOME TAXES The Company operates in U.S., Israel and Canadian tax jurisdictions. Its income is subject to varying rates of tax, and losses incurred in one jurisdiction cannot be used to offset income taxes payable in another. The Company determines its annual effective tax rate at the end of each interim period based on the year to date period results. Since the Company is incorporated in Canada, it is required to use Canada’s statutory tax rate of 26.00 % in the determination of the estimated annual effective tax rate. The Company’s effective tax rate on loss before tax for the three months ended March 31, 2017 of 4.78% (0% - 2016) differs from the Canadian statutory rate of 26% primarily due to recording a valuation allowance on the Canadian deferred tax assets in excess of the remaining Canadian deferred tax liability, resulting in an income tax benefit, and the effect of recording a valuation allowance against deferred tax assets in all other jurisdictions. The Company maintains a valuation allowance on some of its deferred tax assets in certain jurisdictions. A valuation allowance is required when, based upon an assessment of various factors, including recent operating loss history, anticipated future earnings, and prudent and reasonable tax planning strategies, it is more likely than not that some portion of the deferred tax assets will not be realized.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. COMMITMENTS AND CONTINGENCIES Licensing (a) The Company’s manufactured and marketed product, Sci-B-Vac™, is a recombinant third generation hepatitis B vaccine whose sales and territories are governed by the Ferring License Agreement (“License Agreement”). Under the License Agreement, the Company is committed to pay Ferring royalties equal to 7% of net sales (as defined therein). Royalty payments of $2 and $0 were recorded in cost of revenues for the years ended March 31, 2017, and 2016, respectively. In addition, the Company is committed to pay 30% of any and all non-royalty consideration, in any form, received by Company from such sub-licensees (other than consideration based on net sales for which a royalty is due under the License Agreement), provided that the payment of 30% shall not apply to a grant of rights in or relating to: (i) the territory (the “Territory”) as such term was defined prior to an amendment dated January 24, 2005; or (ii) the Berna Territory (as defined in therein). The Company is to pay Ferring the above-mentioned royalties on a country-by-country basis until the date which is ten (10) years after the date of commencement of the first royalty year in respect of such country (“License Period”). Upon expiry of the full term of the first License Period having commenced, the Company shall have the option to extend the License Agreement in respect of all the countries that still make up the Territory (as defined in the License Agreement) (as from the respective date of expiry) for an additional seven (7) years by payment to Ferring of a one-time lump sum payment of $100. Royalties will continue to be payable for the duration of the extended License Periods. When the license has been in effect for, and elapsed after, a seventeen (17) year License Period with respect to a country in the Territory, the Company shall thereafter have a royalty-free license to market (as defined in the License Agreement) in such country and when all the License Periods have expired in each country in the Territory, a royalty-free license to manufacture the product in India and the People’s Republic of China. (b) Under an Assignment and Assumption Agreement, the Company is required to pay royalties to SciGen Singapore equal to 5% of Net Sales. Royalty payments of $1 and $0 were recorded in cost of revenues for the years ended March 31, 2017, and 2016, respectively. Legal Proceedings From time to time, the Company may be involved in certain claims and litigation arising out of the ordinary course of business. Management assesses such claims and, if it considers that it is probable that an asset had been impaired or a liability had been incurred and the amount of loss can be reasonably estimated, provisions for loss are made based on management’s assessment of the most likely outcome. The Company believes that they maintain adequate insurance coverage for any such litigation matters arising in the normal course of business. See Note 7, for the dispute with Kevelt with regard to the DMA. Operating Leases The Company has entered into various non-cancelable lease agreements for its office, lab and manufacturing facilities. These arrangements expire at various times through 2022. Rent expense for the three months ended March 31, 2017 and 2016 was $217 and $95, respectively. The future annual minimum payments under these leases is as follows: Year ending December 31 Remaining 2017 $ 661 2018 717 2019 664 2020 442 2021 442 Thereafter 37 Total $ 2,963 On May 9, 2017, VBI DE signed a one year term extension related to the office space in Cambridge, MA committing it to approximately $144 of rent payments which has been included in the above table.

Revenue by Geographic Region

Revenue by Geographic Region	3 Months Ended
	Mar. 31, 2017
Revenue By Geographic Region
Revenue by Geographic Region	11. REVENUE BY GEOGRAPHIC REGION Three Months Ended March 31 2017 2016 Israel $ 111 $ 40 Asia 14 4 South America 2 - Europe - 4 Total $ 127 $ 48

Property and Equipment, Net by

Property and Equipment, Net by Geographic Region	3 Months Ended
	Mar. 31, 2017
Property And Equipment Net By Geographic Region
Property and Equipment, Net by Geographic Region	12. PROPERTY AND EQUIPMENT, NET BY GEOGRAPHIC REGION March 31, 2017 December 31, 2016 Property and equipment in Israel $ 1,914 $ 1,850 Property and equipment in North America 139 - Total $ 2,053 $ 1,850

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	13. SUBSEQUENT EVENTS On May 15, 2017, the Company entered into an equity distribution agreement (the “Distribution Agreement”) with a registered broker-dealer, as sales agent (the “Sales Agent”), pursuant to which the Company may offer and sell, from time to time, through the Sales Agent its common shares having an aggregate offering price of up to $30 million. The Company is not obligated to sell any common shares under the Distribution Agreement. Subject to the terms and conditions of the Distribution Agreement, the Sales Agent will use commercially reasonable efforts consistent with its normal trading and sales practices, applicable state and federal law, rules and regulations, and the rules of the NASDAQ Capital Market to sell shares from time to time based upon the Company’s instructions, including any price, time or size limits specified by the Company. The Company will pay the Sales Agent a commission of 3.0% of the aggregate gross proceeds from each sale of common shares occurring pursuant to the Distribution Agreement, if any. The Company has also agreed to reimburse the Sales Agent for legal fees and disbursements, not to exceed $50 in the aggregate, in connection with entering into the Distribution Agreement. The Distribution Agreement may be terminated by the Sales Agent or the Company at any time upon ten days’ notice to the other party, or by the Sales Agent at any time in certain circumstances. In connection with the execution of the Distribution Agreement, on May 12, 2017, the Company entered into a waiver agreement (the “Waiver Agreement”)with Perceptive Credit Holdings, LP (“Perceptive Credit”), pursuant to which Perceptive Credit agreed to waive the Company’s obligations to (i) notify Perceptive Credit of the planned filing of a Registration Statement and (ii) include all or a portion of the common shares issuable to Perceptive Credit upon the exercise of a warrant to purchase common shares in the Registration Statement.

Significant Accounting Polici20

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Foreign Currency	Foreign currency The functional and reporting currency of the Company is the USD. Each of the Company’s subsidiaries determines its own respective functional currency, and this currency is used to separately measure each entity’s financial position and operating results. Assets and liabilities of foreign operations with a different functional currency from that of the Company are translated at the closing rate at the end of each reporting period. Profit or loss items are translated at average exchange rates for all the relevant periods. All resulting translation differences are recognized as a component of accumulated other comprehensive loss. Foreign exchange gains and losses arising from transactions denominated in a currency other than the functional currency of the entity involved, are included in operating results.
Use of Estimates	Use of Estimates Preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual amounts could differ from the estimates made. We continually evaluate estimates used in the preparation of the condensed consolidated financial statements for reasonableness. Appropriate adjustments, if any, to the estimates used are made prospectively based upon such periodic evaluation. The significant areas of estimation include determining the deferred tax valuation allowance, the estimated lives of property and equipment and intangible assets, the inputs in determining the fair value of equity based awards and warrants issued as well as the values ascribed to assets acquired and liabilities assumed in the business combination. Actual results may differ from those estimates.
Goodwill and In-process Research and Development	Goodwill and In-Process Research and Development The Company’s intangibles determined to have indefinite useful lives including in-process research and development (“IPR&D”) and goodwill, are tested for impairment annually, or more frequently if events or circumstances indicate that the assets might be impaired. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination. Such circumstances could include, but are not limited to: (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. When evaluating goodwill for impairment, we may first perform an assessment qualitatively whether it is more likely than not that a reporting unit’s carrying amount exceeds its fair value, referred to as a “step zero” approach. If, based on the review of the qualitative factors, we determine it is not more likely than not that the fair value of a reporting unit is less than its carrying value, we would bypass the two-step impairment test. If we conclude that it is more likely than not that a reporting unit’s fair value is less than its carrying amount, we would perform the first step (“step one”) of the two-step impairment test. Step 1 compares the fair value of the Company’s reporting unit to which goodwill was allocated to its carrying value. If the fair value of the reporting unit exceeds its carrying value, no further analysis is necessary. If the carrying amount of the reporting unit exceeds its fair value, Step 2 must be completed to quantify the amount of impairment. Step 2 calculates the implied fair value of goodwill by deducting the fair value of all tangible and intangible assets, excluding goodwill, of the reporting unit, from the fair value of the reporting unit as determined in Step 1. The implied fair value of goodwill determined in this step is compared to the carrying value of goodwill. If the implied fair value of goodwill is less than the carrying value of goodwill, an impairment loss, equal to the difference, is recognized. The Company has established August 31 st The costs of rights to IPR&D projects acquired in an asset acquisition are expensed in the consolidated statements of operations unless the project has an alternative future use. These costs include initial payments incurred prior to regulatory approval in connection with research and development agreements that provide rights to develop, manufacture, market and/or sell pharmaceutical products. IPR&D acquired in a business combination is capitalized as an intangible asset and tested for impairment at least annually until commercialization, after which time the IPR&D is amortized over its estimated useful life. The impairment test compares the carrying amount of the IPR&D asset to its fair value. If the carrying amount exceeds the fair value of the asset, such excess is recorded as an impairment loss.
Fair Value Measurements of Financial Instruments	Fair value measurements of financial instruments Accounting guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The accounting guidance outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company uses quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows: Level 1 — Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 — Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities. Level 3 — Valuations based on inputs that are unobservable and models that are significant to the overall fair value measurement. Financial instruments recognized in the condensed consolidated balance sheet consist of cash, accounts receivable and other current assets, accounts payable and other current liabilities. The Company believes that the carrying value of its current financial instruments approximates their fair values due to the short-term nature of these instruments. The Company does not hold any derivative financial instruments. The carrying amounts of the Company’s long-term assets and long-term liabilities approximate their respective fair values. At March 31, 2017 and December 31, 2016, the fair value of our outstanding debt is estimated to be approximately $15,419 and $15,012, respectively. In determining the fair value of the long-term debt as of March 31, 2017 and December 31, 2016 the Company used the following assumptions: March 31, 2017 December 31, 2016 Long-term debt: Interest rate 12.0 % 12.0 % Discount rate 11.5 % 13.5 % Expected time to payment in months 32 35

Significant Accounting Polici21

Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Schedule of Fair Value of Long-term Debt	In determining the fair value of the long-term debt as of March 31, 2017 and December 31, 2016 the Company used the following assumptions: March 31, 2017 December 31, 2016 Long-term debt: Interest rate 12.0 % 12.0 % Discount rate 11.5 % 13.5 % Expected time to payment in months 32 35

Intangibles (Tables)

Intangibles (Tables)	3 Months Ended
	Mar. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangibles	March 31, 2017 Gross Carrying amount Accumulated Amortization Currency Translation Net Book Value Patents $ 669 $ (349 ) $ 17 $ 337 IPR&D assets 61,500 - (1,860 ) 59,640 $ 62,169 $ (349 ) $ (1,843 ) $ 59,977 December 31, 2016 Gross Carrying amount Accumulated Amortization Currency Translation Net Book Value Patents $ 669 $ (334 ) $ (4 ) $ 331 IPR&D assets 61,500 - (2,324 ) 59,176 $ 62,169 $ (334 ) $ (2,328 ) $ 59,507

Loss Per Share of Common Shar23

Loss Per Share of Common Shares (Tables)	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Schedule of Antidilutive Weighted Average Shares Outstanding	The following potentially dilutive securities outstanding at March 31, 2017 and 2016 have been excluded from the computation of diluted weighted average shares outstanding, as they would be antidilutive: March 31, 2017 March 31, 2016 Warrants 2,068,824 - Stock options and equity awards 3,120,525 - 5,189,349 -

Long-term Debt (Tables)

Long-term Debt (Tables)	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Schedule of Long-term Debt	As at March 31, 2017 and the December 31, 2016, the unamortized debt discount is as follows: March 31, 2017 December 31, 2016 Long-term debt, net of deferred financing costs and unamortized debt discount based on an imputed interest rate of 20.5% of $3,056 and $3,344 at March 31, 2017 and December 31, 2016, respectively $ 12,244 $ 11,956
Schedule of Future Payment of Long-term Debt	The following table summarizes the future principal payments that the Company expects to make for long-term debt: Period ending March 31, Principal payments on Amended Facility and exit fee 2017 $ - 2018 1,600 2019 13,700 $ 15,300

Deferred Revenue and Related 25

Deferred Revenue and Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2017
Deferred Revenue Disclosure [Abstract]
Schedule of Revenues from Related Parties	Three months ended March 31 2017 2016 Services revenues from related parties: OPKO Bio $ 1 $ 7

Stockholders' Equity and Addi26

Stockholders' Equity and Additional Paid-in Capital (Tables)	3 Months Ended
	Mar. 31, 2017
Equity [Abstract]
Schedule of Stock Options Activity	Activity related to stock options is as follows (in thousands, except for weighted average exercise price): Number of Stock Options Weighted Average Exercise Price Balance outstanding at December 31, 2016 2,168 $ 4.45 Granted 316 $ 3.63 Exercised (19 ) $ 3.10 Balance outstanding at March 31, 2017 2,465 $ 4.36 Exercisable at March 31, 2017 1,396 $ 4.42 Options expected to vest at March 31, 2017 1,069 $ 4.29
Schedule of Restricted Stock Units	Information relating to restricted stock units is as follow (in thousands, except for weighted average fair value at grant date): Number of Stock Awards Weighted Average Fair Value at Grant Date Unvested shares outstanding at December 31, 2016 639 $ 3.88 Granted 57 $ 4.72 Vested and exercised (7 ) $ 5.49 Forfeited (33 ) $ 3.90 Unvested shares outstanding at March 31, 2017 656 $ 3.93
Schedule of Stock-based Compensation Expense	The total stock-based compensation expense recorded in the three months ended March 31, 2017 and 2016 was as follows: Three months ended March 31 2017 2016 Research and development $ 185 $ - General and administrative 423 - Cost of revenues 16 - Total stock-based compensation expense $ 624 $ -

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Annual Minimum Lease Payments	The future annual minimum payments under these leases is as follows: Year ending December 31 Remaining 2017 $ 661 2018 717 2019 664 2020 442 2021 442 Thereafter 37 Total $ 2,963

Revenue by Geographic Region (T

Revenue by Geographic Region (Tables)	3 Months Ended
	Mar. 31, 2017
Revenue By Geographic Region
Schedule of Revenue by Geographical Region	Three Months Ended March 31 2017 2016 Israel $ 111 $ 40 Asia 14 4 South America 2 - Europe - 4 Total $ 127 $ 48

Property and Equipment, Net b29

Property and Equipment, Net by Geographic Region (Tables)	3 Months Ended
	Mar. 31, 2017
Property And Equipment Net By Geographic Region
Schedule of Property and Equipment, Net by Geographic Region	March 31, 2017 December 31, 2016 Property and equipment in Israel $ 1,914 $ 1,850 Property and equipment in North America 139 - Total $ 2,053 $ 1,850

Nature of Business and Contin30

Nature of Business and Continuation of Business (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 113,618		$ 104,980
Net cash flows used in operating activities	$ 8,244	$ 1,396

Significant Accounting Polici31

Significant Accounting Policies (Details Narrative) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Fair value of debt outstanding	$ 15,419	$ 15,012

Significant Accounting Polici32

Significant Accounting Policies - Schedule of Fair Value of Long-term Debt (Details) - Fair Value, Inputs, Level 3 [Member]	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Long-term debt, Interest rate	12.00%	12.00%
Long-term debt, Discount rate	11.50%	13.50%
Long-term debt, Expected time to payment in months	32 months	35 months

Intangibles - Schedule of Intan

Intangibles - Schedule of Intangibles (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Intangible assets, Gross	$ 62,169	$ 62,169
Accumulated amortization	(349)	(334)
Currency Translation	(1,843)	(2,328)
Intangible assets, Net	59,977	59,507
Patents [Member]
Intangible assets, Gross	669	669
Accumulated amortization	(349)	(334)
Currency Translation	17	(4)
Intangible assets, Net	337	331
In-Process Research and Development Assets [Member]
Intangible assets, Gross	61,500	61,500
Accumulated amortization
Currency Translation	(1,860)	(2,324)
Intangible assets, Net	$ 59,640	$ 59,176

Loss Per Share of Common Shar34

Loss Per Share of Common Shares - Schedule of Antidilutive Weighted Average Shares Outstanding (Details) - shares	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Antidilutive weighted average shares outstanding	5,189,349
Warrants [Member]
Antidilutive weighted average shares outstanding	2,068,824
Stock Options and Equity Awards [Member]
Antidilutive weighted average shares outstanding	3,120,525

Long-term Debt (Details Narrati

Long-term Debt (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Dec. 06, 2016	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Exit fee	$ 300
Fair value of warrants	2,793
Debt issuance costs	360
Debt discount	$ 3,453	$ 288
Unamortized debt discount		3,056		$ 3,344
Tranche One [Member]
Number of warrants issued to purchase common stock shares	363,771
Warrant exercise price	$ 4.13
Tranche Two [Member]
Number of warrants issued to purchase common stock shares	1,341,282
Warrant exercise price	$ 3.355
Perceptive Credit Holdings, LP [Member]
Line of credit maximum borrowing capacity		6,000
Loan facility, initial advance		3,000
Loan facility, assumed amount		2,361
Proceeds from line of credit	$ 13,200
Line of credit remaining balance	$ 1,800
Line of credit principal outstanding		15,300
Deferred financing costs and unamortized debt discount		3,056
Exit fee		$ 300
Term loan interest rate		The principal on the Amended Facility accrues interest at an annual rate equal to the greater of (a) one-month LIBOR (subject to a 5.00% cap) or (b) 1.00%, plus the Applicable Margin. The Applicable Margin will be 11.00%.
Term loan interest rate		12.00%
Term loan maturity date		Dec. 6, 2019
Perceptive Credit Holdings, LP [Member] | Maximum [Member]
Term loan interest rate		4.00%

Long-term Debt - Schedule of Lo

Long-term Debt - Schedule of Long-term Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
Long-term debt, net of deferred financing costs and unamortized debt discount based on an imputed interest rate of 20.5% of $3,056 and $3,344 at March 31, 2017 and December 31, 2016, respectively	$ 12,244	$ 11,956

Long-term Debt - Schedule of 37

Long-term Debt - Schedule of Long-term Debt (Details) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
Long-term debt, imputed interest rate	20.50%	20.50%
Unamortized debt discount	$ 3,056	$ 3,344

Long-term Debt - Schedule of Fu

Long-term Debt - Schedule of Future Payment of Long-term Debt (Details) $ in Thousands	Mar. 31, 2017USD ($)
Debt Disclosure [Abstract]
2,017
2,018	1,600
2,019	13,700
Total	$ 15,300

Deferred Revenue and Related 39

Deferred Revenue and Related Party Transactions (Details Narrative) - USD ($) $ in Thousands	Mar. 28, 2017	Jul. 30, 2016
Kevelt [Member]
Due to related party	$ 800
Acquisition costs	690
Kevelt [Member] | Common Stock [Member]
Due to related party	400
Kevelt [Member] | Cash [Member]
Due to related party	$ 400
Kevelt [Member]
Refund amount		$ 2,500

Deferred Revenue and Related 40

Deferred Revenue and Related Party Transactions - Schedule of Revenues from Related Parties (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Mar. 31, 2016
OPKO Bio [Member]
Services revenues from related parties	$ 1	$ 7

Stockholders' Equity and Addi41

Stockholders' Equity and Additional Paid-in Capital (Details Narrative) - shares	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Number of options outstanding	2,465,000	2,168,000
Number of stock awards	316,000
2006 Plan [Member]
Number of options outstanding	1,314,000
2013 Plan [Member]
Number of options outstanding	5,000
2014 Plan [Member]
Number of options outstanding	735,000
2016 VBI Equity Incentive Plan [Member]
Percentage of common shares issued and outstanding	10.00%
Number of common shares available for issuance	585,000
2016 Plan [Member]
Number of options outstanding	411,000
Number of stock awards	656,000

Stockholders' Equity and Addi42

Stockholders' Equity and Additional Paid-in Capital - Schedule of Stock Options Activity (Details)	3 Months Ended
	Mar. 31, 2017$ / sharesshares
Equity [Abstract]
Number of Stock Options Outstanding, beginning balance | shares	2,168,000
Number of Stock Options, Granted | shares	316,000
Number of Stock Options, Exercised | shares	(19,000)
Number of Stock Options Outstanding, ending balance | shares	2,465,000
Number of Stock Options, Exercisable | shares	1,396,000
Number of Stock Options expected to vest | shares	1,069
Weighted Average Exercise Price, beginning balance | $ / shares	$ 4.45
Weighted Average Exercise Price, Granted | $ / shares	3.63
Weighted Average Exercise Price, Exercised | $ / shares	3.10
Weighted Average Exercise Price, ending balance | $ / shares	4.36
Weighted Average Exercise Price, Exercisable | $ / shares	4.42
Weighted Average Exercise Price, Options expected to vest | $ / shares	$ 4.29

Stockholders' Equity and Addi43

Stockholders' Equity and Additional Paid-in Capital - Schedule of Restricted Stock Units (Details) - Restricted Stock Units (RSUs) [Member]	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Number of Stock Awards, Unvested shares outstanding beginning balance | shares	639,000
Number of Stock Awards, Granted	$ 57,000
Number of Stock Awards Vested and Exercised | shares	(7,000)
Number of Stock Awards, Forfeited | shares	(33,000)
Number of Stock Awards, Unvested shares outstanding ending balance | shares	656,000
Weighted Avg Fair Value at Grant Date, Unvested shares outstanding beginning balance	$ 3.88
Weighted Avg Fair Value at Grant Date, Granted	4.72
Weighted Avg Fair Value at Grant Date, Vested and Exercised	5.49
Weighted Avg Fair Value at Grant Date, Forfeited	3.90
Weighted Avg Fair Value at Grant Date, Unvested shares outstanding	$ 3.93

Stockholders' Equity and Addi44

Stockholders' Equity and Additional Paid-in Capital - Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Total stock-based compensation expense	$ 624
Research and Development [Member]
Total stock-based compensation expense	185
General and Administrative [Member]
Total stock-based compensation expense	423
Cost of Revenues [Member]
Total stock-based compensation expense	$ 16

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Statutory income tax rate	26.00%
Effective tax rate percentage	4.78%	0.00%
Canada [Member]
Statutory income tax rate	26.00%

Commitments and Contingencies46

Commitments and Contingencies (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Operating leases expiration	2,022
Operating leases, rent expense	$ 217	$ 95
May 9, 2017 [Member]
Payments for rent	$ 144
Ferring License Agreement [Member]
Royalty fees percentage	7.00%
Royalty payments	$ 2	$ 0
Non-royalty consideration percentage	30.00%
License period	The Company is to pay Ferring the above-mentioned royalties on a country-by-country basis until the date which is ten (10) years after the date of commencement of the first royalty year in respect of such country (“License Period”). Upon expiry of the full term of the first License Period having commenced, the Company shall have the option to extend the License Agreement in respect of all the countries that still make up the Territory (as defined in the License Agreement) (as from the respective date of expiry) for an additional seven (7) years by payment to Ferring of a one-time lump sum payment of $100. Royalties will continue to be payable for the duration of the extended License Periods. When the license has been in effect for, and elapsed after, a seventeen (17) year License Period with respect to a country in the Territory, the Company shall thereafter have a royalty-free license to market (as defined in the License Agreement) in such country and when all the License Periods have expired in each country in the Territory, a royalty-free license to manufacture the product in India and the PRC.
Ferring License Agreement [Member] | SciGen Singapore [Member]
Royalty fees percentage	5.00%
Royalty payments	$ 1		$ 0

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Annual Minimum Lease Payments (Details) $ in Thousands	Mar. 31, 2017USD ($)
Commitments and Contingencies Disclosure [Abstract]
Remaining 2,017	$ 661
2,018	717
2,019	664
2,020	442
2,021	442
Thereafter	37
Total	$ 2,963

Revenue by Geographic Region -

Revenue by Geographic Region - Schedule of Revenue by Geographical Region (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenue	$ 127	$ 48
Israel [Member]
Revenue	111	40
Asia [Member]
Revenue	14	4
South America [Member]
Revenue	2
Europe [Member]
Revenue		$ 4

Property and Equipment, Net b49

Property and Equipment, Net by Geographic Region - Schedule of Property and Equipment, Net by Geographic Region (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Property and Equipment, Net by Geographic Region	$ 2,053	$ 1,850
Israel [Member]
Property and Equipment, Net by Geographic Region	1,914	1,850
North America [Member]
Property and Equipment, Net by Geographic Region	$ 139

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member] - Equity Distribution Agreement [Member] - Sales Agent [Member] $ in Thousands	May 15, 2017USD ($)
Percentage of sales commission	3.00%
Maximum [Member]
Available for sale of securities	$ 30,000
Legal fees and disbursements	$ 50